References
Key articles
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: pancreatic adenocarcinoma [internet publication].Full text
Sohal DPS, Kennedy EB, Cinar P, et al. Metastatic pancreatic cancer: ASCO guideline update. J Clin Oncol. 2020 Aug 5:JCO2001364.Full text Abstract
Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 Oct 31;369(18):1691-703.Full text Abstract
Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May 12;364(19):1817-25.Full text Abstract
Balaban EP, Mangu PB, Khorana AA, et al. Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016 Aug 1;34(22):2654-68.Full text Abstract
Ducreux M, Cuhna AS, Caramella C, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26(5 suppl):v56-68.Full text Abstract
Reference articles
1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: pancreatic adenocarcinoma [internet publication].Full text
2. Noë M, Brosens LA. Pathology of pancreatic cancer precursor lesions. Surg Pathol Clin. 2016 Dec;9(4):561-80. Abstract
3. Klimstra DS, Pitman MB, Hruban RH. An algorithmic approach to the diagnosis of pancreatic neoplasms. Arch Pathol Lab Med. 2009 Mar;133(3):454-64.Full text Abstract
4. Hruban RH, Adsay NV. Molecular classification of neoplasms of the pancreas. Hum Pathol. 2009 May;40(5):612-23. Abstract
5. Chari ST, Leibson CL, Rabe KG, et al. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology. 2005 Aug;129(2):504-11.Full text Abstract
6. Sadr-Azodi O, Oskarsson V, Discacciati A, et al. Pancreatic cancer following acute pancreatitis: a population-based matched cohort study. Am J Gastroenterol. 2018 Nov;113(11):1711-9. Abstract
7. Diaconu C, Mateescu D, Bălăceanu A, et al. Pancreatic cancer presenting with paraneoplastic thrombophlebitis--case report. J Med Life. 2010 Jan-Mar;3(1):96-9. Abstract
8. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022 Jan;72(1):7-33.Full text Abstract
9. Carrato A, Falcone A, Ducreux M, et al. A systematic review of the burden of pancreatic cancer in Europe: real-world impact on survival, quality of life and costs. J Gastrointest Cancer. 2015 Sep;46(3):201-11.Full text Abstract
10. Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018 Nov;103:356-87. Abstract
11. Lynch SM, Vrieling A, Lubin JH, et al. Cigarette smoking and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Am J Epidemiol. 2009 Aug 15;170(4):403-13.Full text Abstract
12. Iodice S, Gandini S, Maisonneuve P, et al. Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg. 2008 Jul;393(4):535-45. Abstract
13. Capurso G, Paiella S, Carrara S, et al. Italian registry of families at risk of pancreatic cancer: AISP Familial Pancreatic Cancer Study Group. Dig Liver Dis. 2020 Oct;52(10):1126-30. Abstract
14. Hruban RH, Maitra A, Schulick R, et al. Emerging molecular biology of pancreatic cancer. Gastrointest Cancer Res. 2008 Jul;2(4 Suppl):S10-5.Full text Abstract
15. Petersen GM, de Andrade M, Goggins M, et al. Pancreatic cancer genetic epidemiology consortium. Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):704-10.Full text Abstract
16. Shi C, Hruban RH, Klein AP. Familial pancreatic cancer. Arch Pathol Lab Med. 2009 Mar;133(3):365-74.Full text Abstract
17. Ghaneh P, Costello E, Neoptolemos JP. Biology and management of pancreatic cancer. Gut. 2007 Aug;56(8):1134-52.Full text Abstract
18. Halbrook CJ, Lyssiotis CA, Pasca di Magliano M, et al. Pancreatic cancer: advances and challenges. Cell. 2023 Apr 13;186(8):1729-54.Full text Abstract
19. Hruban RH, Maitra A, Goggins M. Update on pancreatic intraepithelial neoplasia. Int J Clin Exp Pathol. 2008 Jan 1;1(4):306-16.Full text Abstract
20. Hechtman JF. NTRK insights: best practices for pathologists. Mod Pathol. 2022 Mar;35(3):298-305.Full text Abstract
21. Lugo A, Peveri G, Bosetti C, et al. Strong excess risk of pancreatic cancer for low frequency and duration of cigarette smoking: a comprehensive review and meta-analysis. Eur J Cancer. 2018 Nov;104:117-26. Abstract
22. Klein AP, Brune KA, Petersen GM, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 2004 Apr 1;64(7):2634-8.Full text Abstract
23. Vasen HF, Gruis NA, Frants RR, et al. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer. 2000 Sep 15;87(6):809-11.Full text Abstract
24. Aslanian HR, Lee JH, Canto MI. AGA clinical practice update on pancreas cancer screening in high-risk individuals: expert review. Gastroenterology. 2020 Jul;159(1):358-62.Full text Abstract
25. Gandhi S, de la Fuente J, Murad MH, et al. Chronic pancreatitis is a risk factor for pancreatic cancer, and incidence increases with duration of disease: a systematic review and meta-analysis. Clin Transl Gastroenterol. 2022 Mar 28;13(3):e00463.Full text Abstract
26. Malka D, Hammel P, Maire F, et al. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut. 2002 Dec;51(6):849-52.Full text Abstract
27. Aune D, Greenwood DC, Chan DS, et al. Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear dose-response meta-analysis of prospective studies. Ann Oncol. 2012 Apr;23(4):843-52.Full text Abstract
28. Li D, Morris JS, Liu J, et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA. 2009 Jun 24;301(24):2553-62.Full text Abstract
29. Jiao L, Silverman DT, Schairer C, et al. Alcohol use and risk of pancreatic cancer: the NIH-AARP Diet and Health Study. Am J Epidemiol. 2009 May 1;169(9):1043-51.Full text Abstract
30. Hart AR, Kennedy H, Harvey I. Pancreatic cancer: a review of the evidence on causation. Clin Gastroenterol Hepatol. 2008 Mar;6(3):275-82. Abstract
31. Paluszkiewicz P, Smolińska K, Dębińska I, et al. Main dietary compounds and pancreatic cancer risk. The quantitative analysis of case-control and cohort studies. Cancer Epidemiol. 2012 Feb;36(1):60-7. Abstract
32. Kim Y. The association between red, processed and white meat consumption and risk of pancreatic cancer: a meta-analysis of prospective cohort studies. Cancer Causes Control. 2023 Jul;34(7):569-81. Abstract
33. Gianfredi V, Ferrara P, Dinu M, et al. Diets, dietary patterns, single foods and pancreatic cancer risk: an umbrella review of meta-analyses. Int J Environ Res Public Health. 2022 Nov 10;19(22):14787.Full text Abstract
34. Ghadirian P, Simard A, Baillargeon J. Tobacco, alcohol, and coffee and cancer of the pancreas. A population-based, case-control study in Quebec, Canada. Cancer. 1991 May 15;67(10):2664-70. Abstract
35. Bond-Smith G, Banga N, Hammond TM, et al. Pancreatic adenocarcinoma. BMJ. 2012 May 16;344:e2476. Abstract
36. Pannala R, Basu A, Petersen GM, et al. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 2009 Jan;10(1):88-95.Full text Abstract
37. National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. Oct 2023 [internet publication].Full text
38. Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017 Jan;112(1):18-35.Full text Abstract
39. Harsha HC, Kandasamy K, Ranganathan P, et al. A compendium of potential biomarkers of pancreatic cancer. PLoS Med. 2009 Apr 7;6(4):e1000046.Full text Abstract
40. Benke M, Farkas N, Hegyi P, et al. Preoperative serum carbohydrate antigen 19-9 levels cannot predict the surgical resectability of pancreatic cancer: a meta-analysis. Pathol Oncol Res. 2022;28:1610266.Full text Abstract
41. National Institute for Health and Care Excellence. Pancreatic cancer in adults: diagnosis and management. Feb 2018 [internet publication].Full text
42. Sohal DPS, Kennedy EB, Cinar P, et al. Metastatic pancreatic cancer: ASCO guideline update. J Clin Oncol. 2020 Aug 5:JCO2001364.Full text Abstract
43. Zhao W-Y, Luo M, Sun YW, et al. Computed tomography in diagnosing vascular invasion in pancreatic and periampullary cancers: a systematic review and meta-analysis. Hepatobiliary Pancreat Dis Int. 2009 Oct;8(5):457-64. Abstract
44. Catalano C, Laghi A, Fraioli F, et al. Pancreatic carcinoma: the role of high-resolution multislice spiral CT in the diagnosis and assessment of resectability. Eur Radiol. 2003 Jan;13(1):149-56. Abstract
45. Expert Panel on Gastrointestinal Imaging; Qayyum A, Tamm EP, Kamel IR, Allen PJ, et al. ACR appropriateness criteria® staging of pancreatic ductal adenocarcinoma. J Am Coll Radiol. 2017 Nov;14(11S):S560-9.Full text Abstract
46. Wu LM, Hu JN, Hua J, et al. Diagnostic value of diffusion-weighted magnetic resonance imaging compared with fluorodeoxyglucose positron emission tomography/computed tomography for pancreatic malignancy: a meta-analysis using a hierarchical regression model. J Gastroenterol Hepatol. 2012 Jun;27(6):1027-35.Full text Abstract
47. Wu LM, Xu JR, Hua J, et al. Value of diffusion-weighted imaging for the discrimination of pancreatic lesions: a meta-analysis. Eur J Gastroenterol Hepatol. 2012 Feb;24(2):134-42. Abstract
48. Tang S, Huang G, Liu J, et al. Usefulness of 18F-FDG PET, combined FDG-PET/CT and EUS in diagnosing primary pancreatic carcinoma: a meta-analysis. Eur J Radiol. 2011 Apr;78(1):142-50. Abstract
49. Farma JM, Santillan AA, Melis M, et al. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms. Ann Surg Oncol. 2008 Sep;15(9):2465-71. Abstract
50. Tummala P, Junaidi O, Agarwal B. Imaging of pancreatic cancer: an overview. J Gastrointest Oncol. 2011 Sep;2(3):168-74.Full text Abstract
51. Adamek HE, Albert J, Breer H, et al. Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography: a prospective controlled study. Lancet. 2000 Jul 15;356(9225):190-3. Abstract
52. Barish MA, Yucel EK, Ferrucci JT. Magnetic resonance cholangiopancreatography. N Engl J Med. 1999 Jul 22;341(4):258-64. Abstract
53. Lopez Hänninen E, Amthauer H, Hosten N, et al. Prospective evaluation of pancreatic tumors: accuracy of MR imaging with MR cholangiopancreatography and MR angiography. Radiology. 2002 Jul;224(1):34-41. Abstract
54. Dewitt J, Devereaux BM, Lehman GA, et al. Comparison of endoscopic ultrasound and computed tomography for the preoperative evaluation of pancreatic cancer: a systematic review. Clin Gastroenterol Hepatol. 2006 Jun;4(6):717-25. Abstract
55. Hewitt MJ, McPhail MJ, Possamai L, et al. EUS-guided FNA for diagnosis of solid pancreatic neoplasms: a meta-analysis. Gastrointest Endosc. 2012 Feb;75(2):319-31. Abstract
56. Ngamruengphong S, Swanson KM, Shah ND, et al. Preoperative endoscopic ultrasound-guided fine needle aspiration does not impair survival of patients with resected pancreatic cancer. Gut. 2015 Jul;64(7):1105-10. Abstract
57. Rustagi T, Gleeson FC, Chari ST, et al. Safety, diagnostic accuracy, and effects of endoscopic ultrasound fine-needle aspiration on detection of extravascular migratory metastases. Clin Gastroenterol Hepatol. 2019 Nov;17(12):2533-40.e1.Full text Abstract
58. ASGE Standards of Practice Committee, Forbes N, Coelho-Prabhu N, et al. Adverse events associated with EUS and EUS-guided procedures. Gastrointest Endosc. 2022 Jan;95(1):16-26. Abstract
59. Maithel SK, Maloney S, Winston C, et al. Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2008 Dec;15(12):3512-20. Abstract
60. Hori Y; SAGES Guidelines Committee. Diagnostic laparoscopy guidelines. Surg Endosc. 2008 May;22(5):1353-83. Abstract
61. Hariharan D, Constantinides VA, Froeling FE, et al. The role of laparoscopy and laparoscopic ultrasound in the preoperative staging of pancreatico-biliary cancers: a meta-analysis. Eur J Surg Oncol. 2010 Oct;36(10):941-8. Abstract
62. Ta R, O'Connor DB, Sulistijo A, et al. The role of staging laparoscopy in resectable and borderline resectable pancreatic cancer: a systematic review and meta-analysis. Dig Surg. 2019;36(3):251-60. Abstract
63. Hartwig W, Schneider L, Diener MK, et al. Preoperative tissue diagnosis for tumours of the pancreas. Br J Surg. 2009 Jan;96(1):5-20.Full text Abstract
64. Micames C, Jowell PS, White R, et al. Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA. Gastrointest Endosc. 2003 Nov;58(5):690-5. Abstract
65. Siriwardena AK, Siriwardena AM. Pancreatic cancer. BMJ. 2014 Oct 31;349:g6385. Abstract
66. Kloppel G, Adsay NV. Chronic pancreatitis and the differential diagnosis versus pancreatic cancer. Arch Pathol Lab Med. 2009 Mar;133(3):382-7. Abstract
67. Finkelberg DL, Sahani D, Deshpande V, et al. Autoimmune pancreatitis. N Engl J Med. 2006 Dec 21;355(25):2670-6. Abstract
68. Ha J, Choi SH, Kim KW, et al. MRI features for differentiation of autoimmune pancreatitis from pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Dig Liver Dis. 2022 Jul;54(7):849-56. Abstract
69. Exocrine and endocrine pancreas. In: Amin MB, Edge S, Greene F, et al, eds. AJCC cancer staging manual. 8th ed. New York, NY: Springer; 2017.
70. Al-Hawary MM, Francis IR, Chari ST, et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. Gastroenterology. 2014 Jan;146(1):291-304. Abstract
71. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: genetic/familial high-risk assessment: breast, ovarian, and pancreatic [internet publication].Full text
72. Sawhney MS, Calderwood AH, Thosani NC, et al. ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations. Gastrointest Endosc. 2022 May;95(5):817-26. Abstract
73. Corral JE, Mareth KF, Riegert-Johnson DL, et al. Diagnostic yield from screening asymptomatic individuals at high risk for pancreatic cancer: a meta-analysis of cohort studies. Clin Gastroenterol Hepatol. 2019 Jan;17(1):41-53.Full text Abstract
74. US Preventive Services Task Force, Owens DK, Davidson KW, et al. Screening for pancreatic cancer: US Preventive Services Task Force reaffirmation recommendation statement. JAMA. 2019 Aug 6;322(5):438-44.Full text Abstract
75. ASGE Standards of Practice Committee, Storm AC, Fishman DS, et al. American Society for Gastrointestinal Endoscopy guideline on informed consent for GI endoscopic procedures. Gastrointest Endosc. 2022 Feb;95(2):207-215. Abstract
76. Chathadi KV, Chandrasekhara V, Acosta RD, et al; ASGE Standards of Practice Committee. The role of endoscopy in benign diseases of the biliary tract. Gastrointest Endosc. 2015 Apr;81(4):795-803.Full text Abstract
77. ASGE Standards of Practice Committe, Coelho-Prabhu N, Forbes N, et al. Adverse events associated with EGD and EGD-related techniques. Gastrointest Endosc. 2022 Sep;96(3):389-401.Full text Abstract
78. Li D, Xie K, Wolff R, et al. Pancreatic cancer. Lancet. 2004 Mar 27;363(9414):1049-57. Abstract
79. La Torre M, Nigri G, Ferrari L, et al. Hospital volume, margin status, and long-term survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg. 2012 Feb;78(2):225-9. Abstract
80. Hüttner FJ, Fitzmaurice C, Schwarzer G, et al. Pylorus-preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma. Cochrane Database Syst Rev. 2016 Feb 16;(2):CD006053.Full text Abstract
81. Iqbal N, Lovegrove RE, Tilney HS, et al. A comparison of pancreaticoduodenectomy with pylorus preserving pancreaticoduodenectomy: a meta-analysis of 2822 patients. Eur J Surg Oncol. 2008 Nov;34(11):1237-45. Abstract
82. Hüttner FJ, Klotz R, Ulrich A, et al. Antecolic versus retrocolic reconstruction after partial pancreaticoduodenectomy. Cochrane Database Syst Rev. 2022 Jan 11;1:CD011862.Full text Abstract
83. Iqbal N, Lovegrove RE, Tilney HS, et al. A comparison of pancreaticoduodenectomy with extended pancreaticoduodenectomy: a meta-analysis of 1909 patients. Eur J Surg Oncol. 2009 Jan;35(1):79-86. Abstract
84. Jang JY, Kang MJ, Heo JS, et al. A prospective randomized controlled study comparing outcomes of standard resection and extended resection, including dissection of the nerve plexus and various lymph nodes, in patients with pancreatic head cancer. Ann Surg. 2014 Apr;259(4):656-64. Abstract
85. Glanemann M, Shi B, Liang F, et al. Surgical strategies for treatment of malignant pancreatic tumors: extended, standard or local surgery? World J Surg Oncol. 2008 Nov 12;6:123.Full text Abstract
86. Venkat R, Edil BH, Schulick RD, et al. Laparoscopic distal pancreatectomy is associated with significantly less overall morbidity compared to the open technique: a systematic review and meta-analysis. Ann Surg. 2012 Jun;255(6):1048-59. Abstract
87. Cucchetti A, Bocchino A, Crippa S, et al. Advantages of laparoscopic distal pancreatectomy: systematic review and meta-analysis of randomized and matched studies. Surgery. 2023 Apr;173(4):1023-9. Abstract
88. Lyu Y, Cheng Y, Wang B, et al. Assessment of laparoscopic versus open distal pancreatectomy: a systematic review and meta-analysis. Minim Invasive Ther Allied Technol. 2022 Mar;31(3):350-8. Abstract
89. Yin T, Qin T, Wei K, et al. Comparison of safety and effectiveness between laparoscopic and open pancreatoduodenectomy: a systematic review and meta-analysis. Int J Surg. 2022 Sep;105:106799.Full text Abstract
90. van der Gaag NA, Rauws EA, van Eijck CH, et al. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med. 2010 Jan 14;362(2):129-37.Full text Abstract
91. Conroy T, Lambert A, Ducreux M. Adjuvant and neoadjuvant approaches in pancreatic cancer. Curr Opin Oncol. 2023 Jul 1;35(4):326-33. Abstract
92. Andriulli A, Festa V, Botteri E, et al. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol. 2012 May;19(5):1644-62. Abstract
93. Gillen S, Schuster T, Meyer Zum Büschenfelde C, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010 Apr 20;7(4):e1000267.Full text Abstract
94. Morganti AG, Massaccesi M, La Torre G, et al. A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer. Ann Surg Oncol. 2010 Jan;17(1):194-205. Abstract
95. Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC Trial. J Clin Oncol. 2020 Jun 1;38(16):1763-73. Abstract
96. Khorana AA, McKernin SE, Berlin J, et al. Potentially curable pancreatic adenocarcinoma: ASCO clinical practice guideline update. J Clin Oncol. 2019;37(23):2082-8.Full text Abstract
97. Barenboim A, Lahat G, Geva R, et al. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: an intention to treat analysis. Eur J Surg Oncol. 2018 Oct;44(10):1619-23. Abstract
98. Conroy T, Castan F, Lopez A, et al. Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: A randomized clinical trial. JAMA Oncol. 2022 Sep 1:e223829. Abstract
99. Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017 Mar 11;389(10073):1011-24.Full text Abstract
100. Stocken DD, Büchler MW, Dervenis C, et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer. 2005 Apr 25;92(8):1372-81.Full text Abstract
101. Butturini G, Stocken DD, Wente MN, et al; Pancreatic Cancer Meta-Analysis Group. Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg. 2008 Jan;143(1):75-83.Full text Abstract
102. Picozzi VJ, Pisters PW, Vickers SM, et al. Strength of the evidence: adjuvant therapy for resected pancreatic cancer. J Gastrointest Surg. 2008 Apr;12(4):657-61. Abstract
103. Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008 Mar 5;299(9):1019-26.Full text Abstract
104. Regine WF, Winter KA, Abrams R, et al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol. 2011 May;18(5):1319-26.Full text Abstract
105. Valle JW, Palmer D, Jackson R, et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol. 2014 Feb 20;32(6):504-12.Full text Abstract
106. van Roessel S, van Veldhuisen E, Klompmaker S, et al. Evaluation of adjuvant chemotherapy in patients with resected pancreatic cancer after neoadjuvant FOLFIRINOX treatment. JAMA Oncol. 2020 Nov 1;6(11):1733-40.Full text Abstract
107. Gurusamy KS, Kumar S, Davidson BR, et al. Resection versus other treatments for locally advanced pancreatic cancer. Cochrane Database Syst Rev. 2014 Feb 27;(2):CD010244.Full text Abstract
108. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 Oct 31;369(18):1691-703.Full text Abstract
109. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May 12;364(19):1817-25.Full text Abstract
110. Kunzmann V, Siveke JT, Algül H, et al. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2021 Feb;6(2):128-38. Abstract
111. Sultana A, Tudur Smith C, Cunningham D, et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. Br J Cancer. 2008 Jul 8;99(1):6-13.Full text Abstract
112. Sultana A, Smith CT, Cunningham D, et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol. 2007 Jun 20;25(18):2607-15.Full text Abstract
113. Heinemann V, Boeck S, Hinke A, et al. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer. 2008 Mar 28;8:82.Full text Abstract
114. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007 May 20;25(15):1960-6.Full text Abstract
115. Heinemann V, Vehling-Kaiser U, Waldschmidt D, et al. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104). Gut. 2013 May;62(5):751-9. Abstract
116. Hammel P, Huguet F, van Laethem JL, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA. 2016 May 3;315(17):1844-53. Abstract
117. Wainberg ZA, Bekaii-Saab T, Boland PM, et al. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: a phase I/II study. Eur J Cancer. 2021 Jul;151:14-24.Full text Abstract
118. Balaban EP, Mangu PB, Khorana AA, et al. Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016 Aug 1;34(22):2654-68.Full text Abstract
119. Oettle H, Riess H, Stieler JM, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol. 2014 Aug 10;32(23):2423-9.Full text Abstract
120. Vickers MM, Powell ED, Asmis TR, et al. Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo. Eur J Cancer. 2012 Jul;48(10):1434-42. Abstract
121. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997 Jun;15(6):2403-13. Abstract
122. National Institute for Health and Care Excellence. Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer. Sep 2017 [internet publication].Full text
123. ClinicalTrials.gov. A study to assess the effectiveness and safety of irinotecan liposome injection, 5-fluorouracil/leucovorin plus oxaliplatin in patients not previously treated for metastatic pancreatic cancer, compared to nab-paclitaxel+gemcitabine treatment (NAPOLI 3). Aug 2023 [internet publication].Full text
124. Wainberg ZA, Melisi D, Macarulla T, et al. NAPOLI-3: a randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). J Clin Oncol. 2023 Feb 1;41(4):LBA661.
125. Sultana A, Ghaneh P, Cunningham D, et al. Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison. BMC Cancer. 2008 Jul 8;8:192.Full text Abstract
126. Poplin E, Feng Y, Berlin J, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009 Aug 10;27(23):3778-85.Full text Abstract
127. Heinemann V, Labianca R, Hinke A, et al. Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol. 2007 Oct;18(10):1652-9.Full text Abstract
128. Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009 Nov 20;27(33):5513-8.Full text Abstract
129. Colucci G, Labianca R, Di Costanzo F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol. 2010 Apr 1;28(10):1645-51.Full text Abstract
130. Dahan L, Bonnetain F, Ychou M, et al. Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). Gut. 2010 Nov;59(11):1527-34.Full text Abstract
131. Kulke MH, Tempero MA, Niedzwiecki D, et al. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol. 2009 Nov 20;27(33):5506-12.Full text Abstract
132. Wang-Gillam A, Li CP, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016 Feb 6;387(10018):545-57. Abstract
133. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018 Feb 22;378(8):731-9.Full text Abstract
134. Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 Feb;21(2):271-82. Abstract
135. US Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. May 2017 [internet publication].Full text
136. ClinicalTrials.gov. A phase IIb pilot study to assess the efficacy, safety and pharmacodynamic effects of pembrolizumab and BL-8040 in patients with metastatic pancreatic cancer. ClinicalTrials.gov Identifier: NCT02907099. Apr 2018 [internet publication].Full text
137. ClinicalTrials.gov. Phase Ib trial of pembrolizumab and XL888 in patients with advanced gastrointestinal malignancies. ClinicalTrials.gov Identifier: NCT03095781. Apr 2018 [internet publication].Full text
138. ClinicalTrials.gov. A randomized multicenter phase Ib/II study to assess the safety and the immunological effect of chemoradiation therapy (CRT) in combination with pembrolizumab (MK-3475) compared to CRT alone in patients with resectable or borderline resectable pancreatic cancer. ClinicalTrials.gov Identifier:NCT02305186. Sep 2017 [internet publication].Full text
139. Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019 Jul 25;381(4):317-27.Full text Abstract
140. Kindler HL, Hammel P, Reni M, et al. Overall survival results from the POLO trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer. J Clin Oncol. 2022 Dec 1;40(34):3929-39. Abstract
141. Puli SR, Reddy JB, Bechtold ML, et al. EUS-guided celiac plexus neurolysis for pain due to chronic pancreatitis or pancreatic cancer pain: a meta-analysis and systematic review. Dig Dis Sci. 2009 Nov;54(11):2330-7. Abstract
142. Kaufman M, Singh G, Das S, et al. Efficacy of endoscopic ultrasound-guided celiac plexus block and celiac plexus neurolysis for managing abdominal pain associated with chronic pancreatitis and pancreatic cancer. J Clin Gastroenterol. 2010 Feb;44(2):127-34. Abstract
143. Arcidiacono PG, Calori G, Carrara S, et al. Celiac plexus block for pancreatic cancer pain in adults. Cochrane Database Syst Rev. 2011 Mar 16;(3):CD007519.Full text Abstract
144. Amr YM, Makharita MY. Comparative study between 2 protocols for management of severe pain in patients with unresectable pancreatic cancer: one-year follow-up. Clin J Pain. 2013 Sep;29(9):807-13. Abstract
145. Okita M, Otani K, Gibo N, et al. Systematic review and meta-analysis of celiac plexus neurolysis for abdominal pain associated with unresectable pancreatic cancer. Pain Pract. 2022 Sep;22(7):652-61. Abstract
146. National Institute for Health and Care Excellence. Pancreatic cancer. Quality statement 4: pancreatic enzyme replacement therapy. Dec 2018 [internet publication].Full text
147. Cintoni M, Grassi F, Palombaro M, et al. Nutritional interventions during chemotherapy for pancreatic cancer: a systematic review of prospective studies. Nutrients. 2023 Feb 1;15(3):727.Full text Abstract
148. Mahalingam D, Goel S, Aparo S, et al. A phase II study of pelareorep (REOLYSIN(®)) in combination with gemcitabine for patients with advanced pancreatic adenocarcinoma. Cancers (Basel). 2018 May 25;10(6):160.Full text Abstract
149. ClinicalTrials.gov. A study of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion. ClinicalTrials.gov Identifier: NCT02912949. Jan 2021 [internet publication].Full text
150. ClinicalTrials.gov. A randomized phase 2/3 multi-center study of SM-88 in patients with metastatic pancreatic cancer. ClinicalTrials.gov Identifier: NCT03512756. Jun 2021 [internet publication].Full text
151. ClinicalTrials.gov. A multi-center trial to evaluate multiple regimens in metastatic pancreatic cancer. ClinicalTrials.gov Identifier: NCT04229004. Feb 2022 [internet publication].Full text
152. Vandell AG, Eckard J, Hoffman S, et al. In vitro and in vivo anticancer effects of D/L-alpha-metyrosine (SM-88), a novel metabolism-based therapy - Tyme Technologies, Inc. Jun 2020 [internet publication].
153. ClinicalTrials.gov. The ASCEND study: gemcitabine and nab-paclitaxel with CEND-1 or placebo in patients with untreated metastatic pancreatic ductal adenocarcinoma (ASCEND). ClinicalTrials.gov Identifier: NCT05042128. Jan 2022 [internet publication].Full text
154. Charalambous P, Moris D, Karachaliou GS, et al. The efficacy and safety of the open approach irreversible electroporation in the treatment of pancreatic cancer: a systematic review. Eur J Surg Oncol. 2020 Sep;46(9):1565-72. Abstract
155. Rai ZL, Feakins R, Pallett LJ, et al. Irreversible electroporation (IRE) in locally advanced pancreatic cancer: a review of current clinical outcomes, mechanism of action and opportunities for synergistic therapy. J Clin Med. 2021 Apr 10;10(8):1609.Full text Abstract
156. Gajewska-Naryniecka A, Szwedowicz U, Łapińska Z, et al. Irreversible electroporation in pancreatic cancer-an evolving experimental and clinical method. Int J Mol Sci. 2023 Feb 23;24(5):4381.Full text Abstract
157. ClinicalTrials.gov. PANFIRE-3 Trial: Assessing safety and efficacy of irreversible electroporation (IRE) + nivolumab + CpG for metastatic pancreatic cancer. Dec 2022 [internet publication].Full text
158. ClinicalTrials.gov. Irreversible electroporation + nivolumab for patients with metastatic pancreatic cancer (CHECKPOINT). Nov 2022 [internet publication].Full text
159. Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Dec;33(12):1217-38.Full text Abstract
160. Park W, Chawla A, O'Reilly EM. Pancreatic cancer: a review. JAMA. 2021 Sep 7;326(9):851-62. Abstract
161. Huguet F, Girard N, Guerche CS, et al. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol. 2009 May 1;27(13):2269-77.Full text Abstract
162. Ducreux M, Cuhna AS, Caramella C, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26(5 suppl):v56-68.Full text Abstract
163. Nakchbandi IA, Lohr JM. Coagulation, anticoagulation and pancreatic carcinoma. Nat Clin Pract Gastroenterol Hepatol. 2008 Aug;5(8):445-55. Abstract
164. Kocher HM, Alrawashdeh W. Pancreatic cancer. BMJ Clin Evid. 2010 May 19;2010.Full text Abstract
165. Gurusamy KS, Koti R, Fusai G, et al. Somatostatin analogues for pancreatic surgery. Cochrane Database Syst Rev. 2013 Apr 30;(4):CD008370.Full text Abstract
166. Figueras J, Sabater L, Planellas P, et al. Randomized clinical trial of pancreaticogastrostomy versus pancreaticojejunostomy on the rate and severity of pancreatic fistula after pancreaticoduodenectomy. Br J Surg. 2013 Nov;100(12):1597-605. Abstract
167. Topal B, Fieuws S, Aerts R, et al; Belgian Section of Hepatobiliary and Pancreatic Surgery. Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction after pancreaticoduodenectomy for pancreatic or periampullary tumours: a multicentre randomised trial. Lancet Oncol. 2013 Jun;14(7):655-62. Abstract
168. Wente MN, Shrikhande SV, Muller MW, et al. Pancreaticojejunostomy versus pancreaticogastrostomy: systematic review and meta-analysis. Am J Surg. 2007 Feb;193(2):171-83. Abstract
169. Klaiber U, Probst P, Knebel P, et al. Meta-analysis of complication rates for single-loop versus dual-loop (Roux-en-Y) with isolated pancreaticojejunostomy reconstruction after pancreaticoduodenectomy. Br J Surg. 2015 Mar;102(4):331-40. Abstract
170. Deng Y, He S, Cheng Y, et al. Fibrin sealants for the prevention of postoperative pancreatic fistula following pancreatic surgery. Cochrane Database Syst Rev. 2020 Mar 11;3:CD009621.Full text Abstract
171. Tamandl D, Sahora K, Prucker J, et al. Impact of the reconstruction method on delayed gastric emptying after pylorus-preserving pancreaticoduodenectomy: a prospective randomized study. World J Surg. 2014 Feb;38(2):465-75. Abstract
172. Shimoda M, Kubota K, Katoh M, et al. Effect of Billroth II or Roux-en-Y reconstruction for the gastrojejunostomy on delayed gastric emptying after pancreaticoduodenectomy: a randomized controlled study. Ann Surg. 2013 May;257(5):938-42. Abstract
Use of this content is subject to our disclaimer